Aurinia Historical Financial Ratios

AUPH Stock

USD 8.98 0.03 0.34%

Aurinia Pharmaceuticals is presently reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 3.58 or Days Sales Outstanding of 69.52 will help investors to properly organize and evaluate Aurinia Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

About Aurinia Financial Ratios Analysis

Aurinia PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aurinia Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aurinia financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aurinia Pharmaceuticals history.

Aurinia Pharmaceuticals Financial Ratios Chart

As of now, Aurinia Pharmaceuticals' Days Of Inventory On Hand is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Current Ratio is estimated to increase to 6.98, while Price To Sales Ratio is projected to decrease to 6.97.

Dividend Yield Free Cash Flow Yield Operating Cash Flow Per Share Stock Based Compensation To Revenue Pb Ratio Days Of Inventory On Hand

Add Fundamental

Dividend Yield

Dividend Yield is Aurinia Pharmaceuticals dividend as a percentage of Aurinia Pharmaceuticals stock price. Aurinia Pharmaceuticals dividend yield is a measure of Aurinia Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Aurinia Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.

Most ratios from Aurinia Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Days Of Inventory On Hand is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Current Ratio is estimated to increase to 6.98, while Price To Sales Ratio is projected to decrease to 6.97.

	2021	2022	2023	2024 (projected)
Payables Turnover	0.28	1.83	3.27	2.2
Days Of Inventory On Hand	6.5K	1.6K	1.0K	1.1K

Payables Turnover Days Of Inventory On Hand

Aurinia Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.43	0.89	0.2	0.23	0.11	0.03	-0.15	0.43	1.0	0.13	-0.13	-0.12	0.01	-0.16	0.45	-0.24	0.1	0.19	-0.29	-0.18	0.15	-0.31	-0.13	-0.21	-0.18
Ptb Ratio	0.43		0.59	0.74	0.72	0.59	-0.06	0.12	1.0	0.43	0.59	-0.83	-0.76	0.61	0.33	0.44	-0.71	0.08	0.26	-0.55	-0.06	0.04	-0.55	-0.06	-0.06	-0.88
Days Sales Outstanding	0.89	0.59		0.18	0.22	0.14	-0.03	-0.02	0.59	0.89	0.14	-0.33	-0.32	0.08	-0.1	0.47	-0.22	0.21	0.21	-0.21	-0.24	0.07	-0.23	-0.09	-0.17	-0.38
Book Value Per Share	0.2	0.74	0.18		0.89	0.71	-0.16	0.3	0.74	0.2	0.72	-0.6	-0.44	0.7	0.47	0.36	-0.84	-0.03	0.2	-0.63	-0.01	-0.01	-0.62	-0.06	-0.11	-0.68
Free Cash Flow Yield	0.23	0.72	0.22	0.89		0.92	-0.22	0.12	0.72	0.22	0.93	-0.56	-0.31	0.89	0.24	0.34	-0.93	-0.01	-0.18	-0.58	-0.01	0.03	-0.58	-0.03	-0.14	-0.71
Operating Cash Flow Per Share	0.11	0.59	0.14	0.71	0.92		-0.34	0.04	0.59	0.1	0.99	-0.6	-0.32	0.97	-0.03	0.18	-0.81	0.13	-0.39	-0.43	-0.14	-0.1	-0.41	0.11	-0.1	-0.74
Average Payables	0.03	-0.06	-0.03	-0.16	-0.22	-0.34		-0.15	-0.06	0.03	-0.26	0.27	0.02	-0.31	0.04	0.07	-0.12	-0.9	0.25	-0.15	0.9	0.91	-0.23	0.04	0.08	0.2
Capex To Depreciation	-0.15	0.12	-0.02	0.3	0.12	0.04	-0.15		0.12	-0.14	0.01	-0.11	-0.1	0.02	-0.04	0.63	-0.06	0.14	0.33	-0.18	-0.07	-0.24	-0.13	-0.15	-0.1	-0.06
Pb Ratio	0.43	1.0	0.59	0.74	0.72	0.59	-0.06	0.12		0.43	0.59	-0.83	-0.76	0.61	0.33	0.44	-0.71	0.08	0.26	-0.55	-0.06	0.04	-0.55	-0.06	-0.06	-0.88
Ev To Sales	1.0	0.43	0.89	0.2	0.22	0.1	0.03	-0.14	0.43		0.12	-0.12	-0.11	0.01	-0.15	0.46	-0.23	0.1	0.2	-0.3	-0.18	0.14	-0.32	-0.14	-0.21	-0.17
Free Cash Flow Per Share	0.13	0.59	0.14	0.72	0.93	0.99	-0.26	0.01	0.59	0.12		-0.56	-0.29	0.97	-0.01	0.19	-0.85	0.04	-0.41	-0.43	-0.05	0.0	-0.42	0.12	-0.08	-0.73
Roic	-0.13	-0.83	-0.33	-0.6	-0.56	-0.6	0.27	-0.11	-0.83	-0.12	-0.56		0.93	-0.66	-0.13	-0.16	0.49	-0.32	-0.19	0.3	0.26	0.23	0.28	-0.11	-0.05	0.96
Inventory Turnover	-0.12	-0.76	-0.32	-0.44	-0.31	-0.32	0.02	-0.1	-0.76	-0.11	-0.29	0.93		-0.39	-0.13	-0.16	0.32	-0.17	-0.43	0.27	0.11	0.09	0.26	-0.07	-0.06	0.84
Net Income Per Share	0.01	0.61	0.08	0.7	0.89	0.97	-0.31	0.02	0.61	0.01	0.97	-0.66	-0.39		0.01	0.12	-0.79	0.11	-0.44	-0.32	-0.08	-0.06	-0.31	0.25	0.1	-0.8
Days Of Inventory On Hand	-0.16	0.33	-0.1	0.47	0.24	-0.03	0.04	-0.04	0.33	-0.15	-0.01	-0.13	-0.13	0.01		-0.17	-0.26	-0.19	0.38	-0.24	0.14	0.07	-0.25	-0.2	-0.04	-0.14
Payables Turnover	0.45	0.44	0.47	0.36	0.34	0.18	0.07	0.63	0.44	0.46	0.19	-0.16	-0.16	0.12	-0.17		-0.37	-0.03	0.31	-0.42	0.07	0.08	-0.41	-0.26	-0.23	-0.2
Average Inventory	-0.24	-0.71	-0.22	-0.84	-0.93	-0.81	-0.12	-0.06	-0.71	-0.23	-0.85	0.49	0.32	-0.79	-0.26	-0.37		0.34	0.08	0.57	-0.32	-0.36	0.59	0.01	0.11	0.68
Capex To Revenue	0.1	0.08	0.21	-0.03	-0.01	0.13	-0.9	0.14	0.08	0.1	0.04	-0.32	-0.17	0.11	-0.19	-0.03	0.34		-0.07	0.14	-0.97	-0.93	0.23	-0.09	-0.09	-0.18
Cash Per Share	0.19	0.26	0.21	0.2	-0.18	-0.39	0.25	0.33	0.26	0.2	-0.41	-0.19	-0.43	-0.44	0.38	0.31	0.08	-0.07		-0.37	0.03	0.0	-0.37	-0.49	-0.41	-0.03
Pocfratio	-0.29	-0.55	-0.21	-0.63	-0.58	-0.43	-0.15	-0.18	-0.55	-0.3	-0.43	0.3	0.27	-0.32	-0.24	-0.42	0.57	0.14	-0.37		-0.05	-0.07	1.0	0.32	0.53	0.32
Interest Coverage	-0.18	-0.06	-0.24	-0.01	-0.01	-0.14	0.9	-0.07	-0.06	-0.18	-0.05	0.26	0.11	-0.08	0.14	0.07	-0.32	-0.97	0.03	-0.05		0.93	-0.13	0.1	0.21	0.13
Capex To Operating Cash Flow	0.15	0.04	0.07	-0.01	0.03	-0.1	0.91	-0.24	0.04	0.14	0.0	0.23	0.09	-0.06	0.07	0.08	-0.36	-0.93	0.0	-0.07	0.93		-0.16	0.13	0.18	0.07
Pfcf Ratio	-0.31	-0.55	-0.23	-0.62	-0.58	-0.41	-0.23	-0.13	-0.55	-0.32	-0.42	0.28	0.26	-0.31	-0.25	-0.41	0.59	0.23	-0.37	1.0	-0.13	-0.16		0.31	0.51	0.31
Days Payables Outstanding	-0.13	-0.06	-0.09	-0.06	-0.03	0.11	0.04	-0.15	-0.06	-0.14	0.12	-0.11	-0.07	0.25	-0.2	-0.26	0.01	-0.09	-0.49	0.32	0.1	0.13	0.31		0.79	-0.15
Income Quality	-0.21	-0.06	-0.17	-0.11	-0.14	-0.1	0.08	-0.1	-0.06	-0.21	-0.08	-0.05	-0.06	0.1	-0.04	-0.23	0.11	-0.09	-0.41	0.53	0.21	0.18	0.51	0.79		-0.07
Roe	-0.18	-0.88	-0.38	-0.68	-0.71	-0.74	0.2	-0.06	-0.88	-0.17	-0.73	0.96	0.84	-0.8	-0.14	-0.2	0.68	-0.18	-0.03	0.32	0.13	0.07	0.31	-0.15	-0.07

Click cells to compare fundamentals

Aurinia Pharmaceuticals Account Relationship Matchups

Aurinia Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	5.9K	32.69	64.88	4.57	7.34	6.97
Ptb Ratio	6.89	4.02	6.18	1.51	3.41	3.58
Days Sales Outstanding	171.07	422.39	123.37	36.72	50.1	69.52
Book Value Per Share	2.94	3.44	3.7	2.86	2.64	2.51
Free Cash Flow Yield	(0.0337)	(0.0471)	(0.0538)	(0.13)	(0.0265)	(0.0279)
Operating Cash Flow Per Share	(0.68)	(0.59)	(1.22)	(0.56)	(0.23)	(0.25)
Stock Based Compensation To Revenue	14.82	23.31	0.35	0.69	0.26	0.25
Capex To Depreciation	0.0672	5.36	0.54	0.11	0.0616	0.0586
Pb Ratio	6.89	4.02	6.18	1.51	3.41	3.58
Ev To Sales	5.0K	27.43	59.98	3.93	7.61	7.23
Free Cash Flow Per Share	(0.68)	(0.65)	(1.23)	(0.56)	(0.24)	(0.25)
Roic	(0.5)	(0.3)	(0.26)	(0.28)	(0.23)	(0.22)
Net Income Per Share	(0.92)	(0.76)	(1.33)	(0.87)	(1.4)	(0.54)
Payables Turnover	12.73	19.1	0.28	1.83	3.27	2.2
Sales General And Administrative To Revenue	69.67	1.92	3.76	1.47	1.11	1.06
Research And Ddevelopement To Revenue	166.25	1.0	1.12	0.34	0.28	0.27
Capex To Revenue	0.33	0.15	0.0329	0.002179	0.004091	0.003886
Cash Per Share	3.29	3.36	3.6	2.74	2.45	2.32
Pocfratio	(29.7)	(23.45)	(18.76)	(7.71)	(38.48)	(36.56)
Interest Coverage	(67.04)	(25.14)	(2.1K)	(21.78)	(33.04)	(34.69)
Capex To Operating Cash Flow	(0.001639)	(0.11)	(0.009519)	(0.003672)	(0.0215)	(0.0225)
Pfcf Ratio	(29.65)	(21.22)	(18.59)	(7.68)	(37.67)	(35.79)
Days Payables Outstanding	28.67	19.11	1.3K	198.93	111.63	106.05
Income Quality	0.51	0.68	0.87	0.74	0.43	0.41
Roe	(0.57)	(0.45)	(0.25)	(0.27)	(0.21)	(0.22)
Ev To Operating Cash Flow	(24.88)	(19.68)	(17.35)	(6.63)	(39.94)	(37.94)
Pe Ratio	(15.22)	(15.96)	(16.35)	(5.67)	(16.5)	(15.68)
Return On Tangible Assets	(0.48)	(0.39)	(0.23)	(0.34)	(0.14)	(0.15)
Ev To Free Cash Flow	(24.84)	(17.8)	(17.18)	(6.6)	(39.1)	(37.15)
Earnings Yield	(0.11)	(0.0657)	(0.0627)	(0.0612)	(0.0606)	(0.0636)
Intangibles To Total Assets	0.0344	0.0201	0.0155	0.0136	0.009081	0.008627
Net Debt To E B I T D A	3.41	2.56	1.26	0.83	(0.77)	(0.73)
Current Ratio	27.9	13.11	12.63	9.6	5.5	6.98
Tangible Book Value Per Share	2.82	3.36	3.64	2.81	2.6	2.47
Receivables Turnover	2.13	0.86	2.96	9.94	7.29	9.7
Graham Number	9.38	8.19	10.8	7.0	5.69	5.4

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:

How To Invest In Aurinia

Details

Is Aurinia Stock a good investment?

Details

What is Aurinia Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

1.536

Quarterly Revenue Growth

0.243

Return On Assets

(0.02)

Return On Equity

(0.06)

The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Aurinia Historical Financial Ratios

About Aurinia Financial Ratios Analysis

Aurinia Pharmaceuticals Financial Ratios Chart

Dividend Yield

Free Cash Flow Yield

Operating Cash Flow Per Share

Stock Based Compensation To Revenue

Aurinia Pharmaceuticals fundamentals Correlations

Aurinia Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aurinia Pharmaceuticals fundamentals Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Pocfratio
Free Cash Flow Per Share	+ 0.99	Operating Cash Flow Per Share
Net Income Per Share	+ 0.97	Operating Cash Flow Per Share
Net Income Per Share	+ 0.97	Free Cash Flow Per Share

Interest Coverage	- 0.97	Capex To Revenue
Capex To Operating Cash Flow	- 0.93	Capex To Revenue
Average Inventory	- 0.93	Free Cash Flow Yield
Capex To Revenue	- 0.9	Average Payables
Roe	- 0.88	Pb Ratio
Roe	- 0.88	Ptb Ratio